A

Anthropic

Builds Claude AI models with a focus on safety

Manager Enterprise Sales - Pharma

Full-TimePosted on 10/27/2026
$450k - $700k/yr+ Target sales commissions/bonuses
Expert
Bachelor's
Boston, MA, USA+2 moreMore locations: San Francisco, CA, USA | New York, NY, USA
HybridHybrid policy expects staff to work in an office at least 25% of the time.
Sales & Account ManagementAccount Executive
H1B Sponsorship Available

About the job

Requirements
  • At least 10 years of experience in life sciences, including at least 5 years selling into or working within pharma or biotech organizations in R&D, clinical, regulatory, manufacturing, or commercial functions, or related consulting.
  • Experience in leadership roles managing or coaching enterprise sales teams, with measurable revenue outcomes in pharma, biotech, or adjacent life sciences settings.
  • Deep understanding of pharma and/or biotech business models, operations, and economics, including the drug development lifecycle, the regulatory environment (FDA, EMA, GxP, 21 CFR Part 11), and competitive dynamics.
  • Experience managing or overseeing complex, multi-stakeholder sales cycles within pharma or biotech organizations and securing strategic deals by understanding technical requirements and scientific, regulatory, and commercial use cases.
  • Proven experience exceeding revenue targets by effectively managing a team’s pipeline and an evolving sales process.
  • Ability to present confidently across pharma and biotech audiences, from discovery scientists and clinical leaders to C-suite executives.
  • Genuine interest in deploying AI responsibly and motivation to advance the mission of building safe, beneficial AI.
Responsibilities
  • Build and lead a specialized team of Strategic Account Executives covering large pharma and biotech accounts, set growth targets by segment, and coach representatives through the full sales cycle from outbound prospecting to close.
  • Design and oversee sales strategies tailored to pharma and biotech procurement cycles, including R&D and discovery budgets, clinical development and operations, regulatory and CMC investment, commercial budgeting, and enterprise IT and digital transformation programs; translate market and trend analysis into account plans and campaigns that meet and exceed team revenue targets.
  • Identify and prioritize opportunities across target identification and drug discovery, preclinical development, clinical trial design and operations, regulatory affairs and submissions, medical affairs, manufacturing and quality (GxP), pharmacovigilance and drug safety, and commercial functions; partner cross-functionally to differentiate the offering for pharma and biotech use cases.
  • Run a disciplined pipeline and forecasting cadence across the team, manage an evolving sales process, and deliver predictable, coachable performance against quota.
  • Serve as the domain expert across the pharma and biotech value chain, including discovery research, IND-enabling studies, clinical trial operations, NDA/BLA regulatory submissions, tech transfer and manufacturing, post-market safety, and commercial launch; translate that expertise into repeatable playbooks, frameworks, and go-to-market strategies for the team and broader field organization.
  • Partner with C-suite and senior R&D leaders—including CEOs, CIOs, CDOs, CSOs, CMOs, heads of R&D, heads of clinical development, heads of regulatory, and CCOs—to design multi-year AI transformation roadmaps and build trusted-advisor relationships.
  • Partner with Product and Applied AI to translate feedback from discovery scientists, clinical operations teams, regulatory and quality leaders, and commercial teams into product and roadmap input, strengthening the value proposition across the segment.
  • Build strategic relationships with life sciences-focused system integrators, technology vendors, CROs, CDMOs, and industry organizations to scale go-to-market capabilities.
  • Establish the organization’s position as the AI partner of choice across pharma and biotech through conference presentations, white papers, case studies, and participation in industry forums.
  • Codify learnings into playbooks, templates, and best practices, partnering with Marketing and Enablement to scale successful use cases and proof points across pharma and biotech accounts.
Desired Qualifications
  • Deep understanding of buying cycles, decision-making processes, and key pain points across large pharma and biotech and across R&D, clinical, regulatory, manufacturing, and commercial functions.
  • A strategic, analytical approach to assessing the pharma and biotech market, paired with creative, tactical execution to capture opportunities and willingness to work directly on deals alongside the team.
  • Experience developing and refining AI use cases with customers and channel partners across drug discovery, clinical development, regulatory and quality, pharmacovigilance, manufacturing, or commercial functions.
  • Experience building or scaling a specialized sales team from an early stage.
  • Passion for and/or experience with advanced AI systems and their applications in drug discovery and development, with strong conviction around safe, ethical AI development in these contexts.

About the company

Anthropic builds the Claude family of AI models and sells them to businesses, software developers, and consumers, with research on making AI safe and understandable at the center of its work. In 2024 it introduced the Model Context Protocol, an open standard for connecting AI assistants to outside apps and data that OpenAI and Google adopted the next year. People use the Claude app to write and analyze files, programmers hand coding tasks to Claude Code, and companies build Claude into their own products through its API. Anthropic earns money from subscriptions, business plans, and usage-based API fees. Siblings Dario and Daniela Amodei founded Anthropic in 2021 with other former OpenAI employees, and it is based in San Francisco.

Company Size

5,001-10,000

Company Stage

Debt Financing

Total Funding

$242.8B

Headquarters

San Francisco, California

Founded

2021

Get referred to Anthropic

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales are multiplying: Anthropic's yearly revenue pace topped $65 billion in July 2026, over sevenfold since December 2025.
  • IPO plans advanced: October 2026 reports describe investor meetings and a mid-November listing target; staff shares face lockups.
  • Lower office minimum: 627 of 646 Anthropic job posts in October 2026 require at least 25% office time.

What critics are saying

  • Job security rides on growth: Anthropic's IPO prospectus lists $518 billion in cloud and computing bills due in coming years.
  • Defense work stays off-limits: in September 2026, appeals judges voted 2-1 to let the Pentagon keep blacklisting Anthropic.
  • Growth is priced in: Anthropic's valuation reached $965 billion in May 2026, up from $380 billion in February.

What makes Anthropic unique

  • Investors don't control its board alone: Anthropic's independent Long-Term Benefit Trust elects a growing number of directors.
  • It isn't tied to one chipmaker: Claude runs on Nvidia GPUs plus custom AI chips designed by Google and Amazon.
  • It holds back its riskiest model: Claude Mythos 5.1, launched September 2026, goes only to vetted cyberdefenders and life scientists.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Paid Vacation
  • Parental Leave
  • Hybrid Work Options
  • Company Equity

Growth & Insights and Company News

6 month growth

-3%

1 year growth

2%

2 year growth

-3%
Bloomberg
Oct 23rd, 2026
UK commits $127M to AI biosecurity lab backed by OpenAI, Anthropic and Google DeepMind

The UK has announced £100 million ($134 million) for an AI Biosecurity Lab, which OpenAI, Anthropic, and Google DeepMind will support. The funding is part of a package of measures to help the government understand and tackle the risks posed by the technology.

DealStreetAsia
Oct 22nd, 2026
Blackstone eyes AI financing boom, with 7% of its $1.4T assets already exposed

Blackstone sees growing opportunities to finance artificial intelligence (AI) infrastructure, from chips and computing equipment to power generation and data centres. "The needs of capital here are so enormous. It's unprecedented in our lifetimes," President Jon Gray said on the firm's third-quarter earnings call. The firm is reportedly committing $9 billion to a junior-debt tranche in an $18 billion financing package for Anthropic's AI chips and computing infrastructure, part of a broader $60 billion arrangement. In June, its Credit & Insurance business joined a $35 billion financing launched by Apollo and Broadcom for Anthropic. Blackstone is also weighing dedicated investment vehicles alongside broader funds. About 7% of its $1.4 trillion in assets under management is exposed to AI infrastructure. Gray said the firm focuses on physical infrastructure and long-term contracted assets to manage risks such as technological obsolescence.

PR Newswire
Oct 22nd, 2026
Cube joins Claude's connector directory, bringing live, permissioned FP&A data to finance teams

Cube, an agentic financial planning and analysis (FP&A) platform, has partnered with Anthropic to make its financial model available inside Claude. Finance teams can now add Cube through Claude's connector directory. The connector gives Claude the chart of accounts, business logic, and enterprise permissions behind a company's numbers. Each user sees only the data they are authorised to access, and figures can be traced to the source transaction. Users sign in through a secure OAuth flow, with no API keys to manage. They can then ask questions in plain English, such as comparing actuals with forecast, or set up new scenarios. "Data tells AI what the numbers are. Financial context tells AI what the numbers mean," said Christina Ross, founder and chief executive officer of Cube. The Cube MCP Server is available now.

Associated Press
Oct 22nd, 2026
Qlik's MCP server joins Anthropic's Claude Directory, bringing governed data to Claude

Qlik has made its Model Context Protocol (MCP) server available through Anthropic's Claude Directory. Claude users can now connect governed Qlik data, analytical logic, and selected analytics workflows more easily. The server gives Claude access to data lineage, trust signals, and business metrics from Qlik Cloud. Users can search apps and datasets, ask questions in natural language, and create dashboards with prompts. Teams no longer need to rebuild business logic elsewhere. Access runs on OAuth-based authentication and existing Qlik Cloud permissions, so enterprise controls stay in place. "Customers adopting Claude want more than an LLM hooked to raw records," said Josh Good, vice president of corporate strategy at Qlik. The company announced the news on October 22, 2026.

CNBC
Oct 21st, 2026
Anthropic previews Claude Duet, a proactive AI agent rivalling Meta's Muse and OpenAI's Dots

Anthropic on Wednesday announced a preview of Claude Duet, an AI agent for small businesses and professionals. It can send daily briefs, keep tabs on connected apps, and carry out tasks such as building dashboards, scheduling meetings, and creating financial forecasts. The launch follows Meta's Muse, which topped Apple's App Store after its launch last month, and OpenAI's Dots. Meta chief executive officer Mark Zuckerberg said more than 10 million people in the US and Canada have set up Muse agents. Anthropic said Duet is still early and "might misread a thread or miscalibrate what's urgent." Personal errands, such as booking tickets, are not "quite as strong." A waitlist is open. Pro and Max subscribers can use the preview through a standalone app or the Claude website.